Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-20 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-20 Recombinant Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL20 Products |
| Gene Delivery | IL-20 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL20 Products |
| Benchmark Ab | Anti-IL-20 Recombinant Antibody Biosimilar based on clinical candidate sequence (Fletikumab) for positive control. |
View IL20 Products |
| Validator | IL-20 siRNA Set For knockdown verification in target-validation assays. |
View IL20 Products |
| Related Target A | IL-20RA Receptor alpha subunit forming the IL-20R1 complex. Crucial for receptor binding assays. |
View IL20RA Products |
| Related Target B | IL-20RB Shared receptor beta subunit. Required for functional heterodimer assembly and signaling. |
View IL20RB Products |
| Related Target C | IL-19 Homolog sharing the IL-20RB receptor subunit; critical for off-target and selectivity screening. |
View IL19 Products |
| Related Target D | IL-24 Homolog sharing the IL-20RB receptor subunit; critical for selectivity profiling. |
View IL24 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor heterodimerization complexity | High-purity monomers and lentiviral vectors for stable dual-receptor expression (IL-20RA/IL-20RB) in host cell lines. |
| Cross-reactivity within IL-10 family homologs | Selectivity panels including IL-19 and IL-24 proteins strictly verified by Mass Spectrometry and HPLC. |
| Lack of Reliable Controls | Recombinant Fletikumab biosimilar available as a standard positive control. |
| False Positives in Functional Assays | Sequence-verified siRNA sets included for target-specific knockdown verification. |
Live IL-20 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-20 therapeutics is intensifying, with major players shifting focus from traditional systemic mAbs to tissue-targeted bi-specifics and localized delivery systems. As first-generation therapies reach clinical inflection points in psoriasis and rheumatoid arthritis, the next wave of R&D is targeting diabetic nephropathy, hepatic fibrosis, and tissue remodeling disorders where IL-20 plays a non-redundant pathological role.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Novo Nordisk, BMS | Psoriasis, Rheumatoid Arthritis | Neutralization Assay (Need bioactive HEK293-expressed IL-20) |
| Bispecific Antibody | Academic Institutes, Biotech startups | Inflammatory Bowel Disease (IBD) | Dual-targeting Validation (Need IL-20 and IL-23/IL-17 homolog panels) |
| Small Molecule Inhibitors | Global Pharma | Fibrosis, Diabetic Nephropathy | Receptor-ligand blocking assays (Need IL-20RA/IL-20RB extracellular domains) |